Topic: Myriad

JD Supra Corporate Brief: European Cookies, Gene Patents, Reasonable Customers, Liquidity Requirements

Why wait for the holidays? Give yourself a gift today: an email subscription to the JD Supra Corporate Brief. It’s informative, entertaining, and – best of all – comes in your size… Those Europeans sure are particular about their cookies, aren’t they? (Cedric Burton, Christopher Kuner, and Anna Pateraki at Wilson Sonsini) The EEOC just… Read more »

JD Supra Corporate Brief: Drug Pricing in China, Corruption in Brazil, Climate Change in Congress, Antitrust Law in Europe

A Friday in July and you’re reading the JD Supra Corporate Brief? Does it get any better? China is questioning 60 pharmaceutical companies about their drug pricing (Dechert) Myriad is going on the litigation offensive to protect its BRCA1 and BRCA2 patents (MBHB) Even the ITC is targeting patent trolls… (Duane Morris) Companies operating in… Read more »

Inevitable? Supreme Court Myriad Ruling Leads to Challenge of Human Stem Cell Patent

When the Supreme Court ruled last month that human genes were not patent eligible, writes attorney Antoinette Konski of Foley & Lardner: “[m]any in the biotech community were relieved that the Supreme Court in Myriad limited its holding of patent-ineligibility to isolated, naturally-occurring genes. However, patent practitioners cautioned that Myriad’s holding could potentially be applied… Read more »

Myriad Genetics Ruling That DNA Is Patent-Eligible

We’re seeing significant interest in the Myriad Genetics case, Association for Molecular Pathology v. U.S. Patent and Trademark Office, following the July 29, 2011, Court of Appeals for the Federal Circuit ruling that isolated DNA are patent-eligible subject matter. We’ll continue to update this reading list as additional commentary and analysis comes in: A Non-infringing… Read more »